Lantheus (NASDAQ:LNTH) Stock Price Down 3.3%

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares dropped 3.3% on Friday . The stock traded as low as $118.51 and last traded at $119.51. Approximately 891,957 shares changed hands during trading, a decline of 15% from the average daily volume of 1,045,906 shares. The stock had previously closed at $123.62.

Analyst Ratings Changes

LNTH has been the subject of several research reports. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. JMP Securities raised their price objective on Lantheus from $100.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday. B. Riley raised their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. SVB Leerink increased their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Mizuho increased their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $113.86.

Lantheus Trading Down 0.2 %

The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The company has a fifty day moving average of $81.01 and a 200-day moving average of $67.35. The firm has a market capitalization of $8.55 billion, a PE ratio of 18.87 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.11. The business had revenue of $369.98 million during the quarter, compared to analyst estimates of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the sale, the insider now directly owns 80,244 shares in the company, valued at $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold 32,269 shares of company stock valued at $2,557,300 over the last three months. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. UMB Bank n.a. lifted its stake in Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares during the period. Principal Securities Inc. bought a new position in Lantheus during the fourth quarter worth about $28,000. Fidelis Capital Partners LLC bought a new position in Lantheus during the first quarter worth about $34,000. Finally, FinTrust Capital Advisors LLC lifted its stake in Lantheus by 53.6% during the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.